

FOR IMMEDIATE RELEASE

GlaxoSmithKline Welcomes New Canadian Diabetes Association Clinical Practice Guidelines

AVANDIA® continues to be recommended second line after metformin

MISSISSAUGA, ON (September 18, 2008) – GlaxoSmithKline Inc. (GSK) welcomes today's release of *Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes*. These provide important guidance for Canadians, and continue to support the use of AVANDIA® (rosiglitazone maleate) as an important treatment option in the management of type 2 diabetes.

The new evidence-based Guidelines were developed by the Canadian Diabetes Association's (CDA) Expert Committee, the leading researchers and physicians treating diabetes in Canada. More information about diabetes and the new Guidelines is available at the CDA Web site at www.diabetes.ca.

"We congratulate all those involved in the effort to develop the new CDA Clinical Practice Guidelines, and welcome their release," said Tjark Reblin, Chief Medical Officer at GlaxoSmithKline. "These new Guidelines, which reflect the latest evidence-based expert consensus, will assist physicians in making individualized treatment decisions in the best interests of their patients, including strategies to achieve and maintain glycemic targets."

The Guidelines reaffirm AVANDIA's role as a treatment for type 2 diabetes. When lifestyle management is not enough to control diabetes, the Guidelines recommend metformin as an initial treatment in most patients, followed as necessary by the addition of a medication from a number of different classes, including thiazolidinediones (TZDs) such as AVANDIA®, an insulin sensitizer.

"These Guidelines represent a significant body of work, and we believe that Canadian physicians and patients will benefit from increased access to these Guidelines, given the epidemic of type 2 diabetes in Canada," said Dr. Reblin. "As such GSK is supporting the CDA in its dissemination of the new Guidelines to Canadian physicians."

About GlaxoSmithKline

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and health-care companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. GSK is Canada's largest biopharmaceutical employer, and has been consistently recognized as one of the 50 Best Employers in Canada. GSK is an Imagine Caring Company and is among the top

15 investors in Canadian research and development, investing more than \$178 million in 2007 alone. For company information, please visit www.gsk.ca.

Important Information About AVANDIA® (rosiglitazone maleate)

AVANDIA® (rosiglitazone maleate) is indicated for use as an adjunct to diet and exercise to reduce insulin resistance and improve glycemic control in patients with type 2 diabetes mellitus: as monotherapy, in patients not controlled by diet and exercise alone and for whom metformin is inappropriate because of contraindications or intolerance; in combination with metformin, when diet and exercise plus metformin do not result in adequate glycemic control; or in combination with a sulfonylurea, in patients who show intolerance to metformin or for whom metformin is contraindicated, when diet and exercise plus the sulfonylurea or AVANDIA® monotherapy do not result in adequate glycemic control. AVANDIA® should be added to (not substituted for) the monotherapy agent. When used in combination with a sulfonylurea, the dose of AVANDIA® should not exceed 4 mg daily. AVANDIA® is not indicated for use in combination with insulin or with metformin and a sulfonylurea (triple therapy). Rosiglitazone acts primarily by increasing insulin sensitivity and improves beta-cell function, underlying causes of type 2 diabetes. The most common side effects reported in clinical trials with rosiglitazone were upper respiratory tract infection, headache, and back pain. Rosiglitazone is not for everyone. Rosiglitazone should not be used in patients with heart failure or serious liver problems, or in patients who are pregnant.

For further information on AVANDIA®, please see full Product Monograph (May 2008) at www.gsk.ca.

® AVANDIA is a registered trademark, used under license by GlaxoSmithKline Inc.

- 30 -

For more information, please contact:

Corporate Communications
GlaxoSmithKline Inc.
905-819-3363